Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narmafotinib + mFOLFIRINOX in Metastatic Pancreatic Cancer
NCT07026279Phase 2Active, not recruiting
- Sponsor
- Amplia Therapeutics Limited
- Start
- Aug 2025
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of narmafotinib in pancreatic cancer (PC), sponsored by Amplia Therapeutics Limited. Started Aug 2025; status: active, not recruiting.
02
Drugs
narmafotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07026279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07026279.